The Korea Times
Sam Chun Dang Pharm, which once topped the Kosdaq by market capitalization, has been experiencing heightened volatility in recent weeks, drawing intense investor attention, industry officials said Monday. The stock briefly climbed to 1.18 million won ($783) per share late last month, driven by strong optimism over its oral insulin project and a licensing deal with a U.S. partner, propelling the company to the top of the Kosdaq rankings. However, skepticism over its research capabilities and the sustainability of the gains soon triggered controversy, sending the share price plunging by nearly half within just three days. Company CEO Chun In-seok, the firm’s largest shareholder, moved to contain the fallout by scrapping a planned large-scale block deal. Earlier on Monday, the company said Chun had withdrawn his plan, first disclosed on March 24, to carry out a 250 billion won block sale. He had intended to sell 265,700 shares through after-hours transactions between April 23 and May 22 to raise funds for gift tax and other tax liabilities. Reversing the course, he cited mounting market s
Go to News Site